Fidelity Select Health Care Portfolio Q4 2025 Commentary

Why It Matters

The sector’s outperformance underscores health‑care’s growth engine, while the fund’s positioning signals where investors may capture excess returns amid regulatory and market headwinds.

Key Takeaways

• Health‑care sector rose 11.47% Q4 2025, outpacing S&P 500.
• FSPHX returned 11.10%, slightly below MSCI health‑care index.
• Underweight pharma, especially Eli Lilly, hurt relative performance.
• Fund overweight biotech and life‑sciences tools for 2026 growth.
• Risks: entitlement reform, pricing legislation, emerging‑market FX volatility.

Pulse Analysis

The fourth quarter of 2025 marked a breakout for the U.S. health‑care sector, which climbed 11.47%—far outpacing the S&P 500’s modest 2.66% gain. Demographic tailwinds, sustained demand for chronic‑disease therapies, and a wave of FDA approvals for gene‑editing and digital health platforms helped lift both pharmaceuticals and biotech. Investors also rewarded the sector’s defensive character as inflationary pressures nudged capital toward stable, cash‑generating businesses, reinforcing health‑care’s reputation as a safe‑haven during market volatility.

Fidelity’s Select Health Care Portfolio (FSPHX) captured most of the rally, delivering an 11.10% return, but it lagged the MSCI health‑care index because the manager kept a light exposure to large‑cap pharma, especially Eli Lilly, which outperformed its peers. Conversely, the fund’s overweight stance in innovative biotech and life‑sciences tools generated strong stock‑selection credit, offsetting the pharma shortfall. With a 0.63% expense ratio, a semi‑annual dividend of $0.13 and $6.2 billion in assets under management, the fund offers a focused, high‑conviction play for investors seeking sector‑specific growth.

Looking ahead to 2026, Fidelity plans to deepen its exposure to breakthrough biotech and bioprocessing firms while adding select large‑cap pharma that show improving fundamentals. The outlook, however, is tempered by policy risks such as potential entitlement‑reform legislation and tighter drug‑pricing rules, as well as broader macro concerns like emerging‑market currency swings. For investors, the combination of attractive relative valuations and Fidelity’s research‑driven positioning could translate into material upside, provided the regulatory environment remains manageable.